<DOC>
	<DOC>NCT00311012</DOC>
	<brief_summary>This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.</brief_summary>
	<brief_title>SPP100 Dose Finding Study in Japan</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>1. Mild to moderate essential hypertension 2. Age: ≥20 years old and &lt;80 years old (at time informed consent obtained) 3. Sex: N/A 4. Admission status: Outpatient 1. Pregnant women, lactating women, potentially pregnant women, or women who wish to become pregnant 2. Patients having a mean sitting diastolic blood pressure of ≥110 mmHg and/or a mean sitting systolic blood pressure of ≥180 mmHg at either Visit 2 or 3 3. Patients with secondary hypertension as a complication or patients suspected of having secondary hypertension(due to aortic coarctation, primary aldosteronism, coarctation of renal artery, renal hypertension 4. Patients suspected of having malignant hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Hypertension, Aliskiren</keyword>
</DOC>